32 results
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
IDSA Recommendations ... HIV-AIDS Preventing Clinical ... preventing clinical ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... • In rare cases ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome - Treatment ... Ulcers: • Treatment ... • Azathioprine and ... #management #pharmacology ... #rheumatology
Non-HCV infectious mixed cryoglobulinemia vasculitis - Diagnosis, causes and management - French Vasculitis Study Group

< 5%
vasculitis - Diagnosis, causes ... and management ... cryoglobulinemia vasculitis Clinical ... neuropathy Treatment ... Cryoglobulinemia #Vasculitis #Rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Erythematosus (SLE) Clinical ... autoantibodies that will cause ... Puncture, EEG Treatment ... CNS #neurology #rheumatology ... diagnosis #management #treatment
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
SLE) - Diagnosis and ... 40, F:M 9:1 • Clinical ... Positive in 60-80% of cases ... life-threatening • Treatment ... Management #Summary #rheumatology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
accumulation of clinical ... Assessment • Clinical ... Drugs, Unknown cause ... Treatment: • ... #summary #rheumatology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
Risk factors: Critical ... without other cause ... : 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... MDRTB #management #Treatment ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
Disseminated Intravascular Coagulation (DIC) Overview

Increased Clotting and Consumption of Clotting Factors

Findings:
 • Bleeding
 • Recent history
organ damage Clinical ... + Bleeding Treatment ... Treat primary cause ... #treatment #management ... #hematology